Neurotrauma Treatment Market Size, Share, and Growth Forecast 2026 - 2033

The global neurotrauma treatment market size is likely to be valued at US$6.4 billion in 2026 and is estimated to reach US$9.9 billion by 2033, growing at a CAGR of 6.4% during the forecast period from 2026 to 2033, driven by the rising burden of traumatic brain and spinal cord injuries and improving acute care protocols. Advances in neuromodulation and regenerative therapies are also widening treatment options.

Driver - Rising Injury Burden to Push Acute and Long-term Care Needs

Neurotrauma creates both urgent and lifelong care needs. The Global Burden of Disease 2021 analysis estimated 20.84 million new TBI cases and 574,502 new spinal cord injury (SCI) cases worldwide. Prevalent cases reached 37.93 million for TBI and 15.4 million for SCI. Falls were the leading risk factor for both conditions, followed by motor vehicle road injuries. Age-standardized TBI prevalence was highest in Eastern Europe, at 888.9 per 100,000.

The burden is also visible in national data. The Centers for Disease Control and Prevention (CDC) reported about 214,110 TBI-related hospitalizations in the U.S. in 2020 and 68,663 deaths in 2023, or about 190 a day. People aged 75 and older accounted for about 32% of hospitalizations. An aging population adds to fall-related injuries and long-term care demand.

Better Acute Protocols and Diagnostics to Reinforce Treatment Uptake

Clear protocols are improving early treatment. The 2024 AO Spine and Praxis guidelines favor surgery within 24 hours of injury for adults with acute SCI when medically feasible. The guidelines were sponsored by AO Spine and the Praxis Spinal Cord Institute. They also advise keeping mean arterial pressure at 75 to 80 mmHg or higher for three to seven days. Faster, standardized care increases the share of patients who receive surgery and critical care.

Diagnostics are advancing as well. In April 2024, Abbott announced FDA clearance of its i-STAT TBI cartridge, the first whole blood test to help evaluate suspected mild TBI. It gives results in about 15 minutes at the point of care. Earlier Abbott clearances covered a plasma test in 2021 and a laboratory blood test in 2023. Objective triage can help clinicians decide who needs a CT scan, which improves flow into treatment pathways.

Restraint - Limited Drug Options and Uneven Evidence May Hold Back Growth

Few drugs have changed outcomes in neurotrauma. NervGen notes that no pharmacologic treatments are approved for SCI. The CRASH-3 trial tested tranexamic acid in 12,737 adults with TBI treated within three hours. It was published in The Lancet in 2019. The primary result was not significant, with a risk ratio of 0.94. Benefit appeared in mild-to-moderate injury, with a risk ratio of 0.78, but not in severe injury.

Access is another barrier. CDC estimates exclude TBIs treated only in emergency departments, primary care, or urgent care, so the true burden is likely higher. Neurosurgical and intensive care capacity varies widely, particularly in low-resource settings. Rehabilitation is also costly and long. Patients may need months of therapy, and many injuries leave lasting disability. These gaps can delay treatment and limit the use of newer therapies.

Opportunity - Neuromodulation and Rehabilitation Technologies to Expand Recovery Options

Neuromodulation is opening new recovery options for SCI. ONWARD Medical's ARC-EX uses transcutaneous electrical spinal cord stimulation to improve hand function in people with severe SCI. The company supplied 70 ARC-EX systems in the first quarter of 2026 and reported system sales revenue of EUR 1.3 million. First systems have also been delivered for home use, including to U.S. veterans. ARC-EX is described as cleared for commercial sale in the U.S. and Europe.

The pipeline is widening. The investigational ARC-IM implant is being tested in the randomized, sham-controlled Empower BP study, which plans about 20 centers across six countries. It targets blood pressure instability after SCI. The first implant took place at Craig Hospital in Denver, and 12 U.S. sites are activated and recruiting. Success could extend therapy from rehabilitation clinics to implanted care.

Regenerative and Neuroprotective Drugs to Fill an Unmet Pharmacologic Gap

Drug developers are targeting the lack of approved SCI therapies. NervGen reported that NVG-291 produced a 2.6-fold greater improvement in GRASSP total score than placebo in the CONNECT SCI study. In the patient global impression, 6 of 8 NVG-291 participants reported much or very much improvement, versus 3 of 9 on placebo. The sample was small, at 8 to 9 participants per arm, and the figures are company-reported. NVG-291 holds FDA Fast Track designation.

Other approaches are earlier. In July 2025, Amphix Bio's "dancing molecules" therapy received FDA Orphan Drug Designation for acute SCI. In a 2021 Science study, a single injection helped severely injured mice walk again within four weeks. The therapy comes from the lab of Samuel Stupp at Northwestern University. Human data are still needed.

Treatment Type Insights

Surgical interventions are predicted to lead with a share of about 46.8% in 2026, as severe TBI and SCI often need urgent surgery and intensive monitoring. Procedures include craniotomy, decompression, spinal stabilization, and intracranial pressure monitoring. The 2024 spine guidelines favor surgery within 24 hours. This keeps demand for neurosurgical tools and implants steady.

The neuromodulation and rehabilitation segment is estimated to be the fastest-growing treatment type over the forecast period, as recovery technologies move into clinics and homes. ARC-EX is now available in over 100 clinics across the U.S. and Europe. These therapies address long-term disability, which acute surgery cannot fix. Reimbursement and training will shape adoption.

Injury Type Insights

Traumatic brain injury is anticipated to dominate with a share of around 72.6% in 2026, as incidence is far higher than that of SCI. Global data show 20.84 million new TBI cases against 574,502 new SCI cases in 2021. In the U.S., males were nearly twice as likely as females to be hospitalized for TBI. Demand spans emergency, surgical, and rehabilitation care.

Spinal cord injury is expected to be the fastest-growing injury type over the forecast period, as new devices and drug candidates reach clinical stages. ARC-EX is on the market, while NVG-291 and ARC-IM are in development. The segment is smaller but has high unmet need and high per-patient costs.

North America Neurotrauma Treatment Market Trends

North America is predicted to dominate with a global share of approximately 38.4% in 2026, supported by advanced trauma systems, strong neurosurgical capacity, and early adoption of new devices and diagnostics. The CDC reports that TBI-related deaths reached 68,663 in 2023. The region is also the first market for several recovery technologies. Abbott's whole blood test can be used outside emergency rooms, in facilities such as urgent care clinics that hold the required certificates.

U.S. Neurotrauma Treatment Market Trends

A share of nearly 87.3% is expected to be held by the U.S. in 2026 in North America, as it has a large trauma network and active clinical research. CDC data show males had an age-adjusted TBI hospitalization rate of 79.9 per 100,000, versus 43.7 for females. The FDA has cleared Abbott's whole blood TBI test and ONWARD's ARC-EX. Several SCI candidates are in U.S. trials.

Asia Pacific Neurotrauma Treatment Market Trends

Asia Pacific is anticipated to be the fastest-growing region, supported by a high burden of road traffic injuries, expanding emergency trauma networks, and rising neurosurgical capacity across major economies such as China, India, Japan, and Australia. Rapid urbanization, increasing motorization, and dense transport corridors contribute to demand for timely diagnosis and treatment of traumatic brain injuries, spinal cord injuries, and other severe neurological trauma. The need for emergency imaging, intensive care, neurosurgical intervention, and long-term rehabilitation is strengthening the role of neurotrauma services within regional healthcare systems.

China Neurotrauma Treatment Market Trends

China will likely lead in Asia Pacific in 2026 with a share of about 38.2%. A national survey conducted in 2013 estimated 66,374 new traumatic SCI cases a year and about 759,302 prevalent patients. Incidence was 63.2 per million in men versus 36.9 in women. Falls caused 55.2% of prevalent cases, and motor vehicle collisions caused 26.5%. Large long-term patient numbers support steady demand for surgery and rehabilitation.

India Neurotrauma Treatment Market Trends

In 2026, India is projected to account for a share of just about 16.4% in Asia Pacific, as road injuries create a large trauma burden. The Ministry of Road Transport and Highways reported 480,583 road accidents, 172,890 deaths, and 462,825 injuries in 2023. Accidents rose 4.2% from the previous year. Two-wheeler riders made up 44.8% of road deaths. Head and spine injuries are therefore a major concern.

Europe Neurotrauma Treatment Market Trends

Europe will witness steady growth over the forecast period with a share of roughly 13.5% in 2026 globally, due to well-organized trauma care and an aging population. Falls among older adults are a major cause of head injury. ONWARD Medical's ARC-EX is cleared for commercial sale in Europe, and the Empower BP study includes sites in France, Germany, Spain, and the U.K.

Germany Neurotrauma Treatment Market Trends

Germany is predicted to register a substantial share of approximately 28.9% in 2026 in Europe, as it has a dense hospital network and strong neurosurgical expertise. The Hannelore Kohl Foundation cites Destatis data of about 270,000 inpatient cases a year with head injury as the main diagnosis. It also reports over 7,000 deaths a year from head injuries. Including outpatient cases, it estimates about 670,000 cases a year, with about 100,000 people needing long-term care.

U.K. Neurotrauma Treatment Market Trends

A share of nearly 17.3% is predicted to be held by the U.K. in 2026 in Europe. Headway reported 123,969 head injury admissions in the U.K. in 2023-24. Total acquired brain injury admissions were 335,409. Males were 1.5 times more likely than females to be admitted for head injury. Admissions have fallen since 2020, mainly as head injury admissions dropped. The U.K. is also a planned site for ONWARD's Empower BP study.

The global neurotrauma treatment market is fragmented, with large neurosurgical and critical care companies alongside specialized recovery and diagnostics firms. Medtronic, Integra LifeSciences, Stryker, and B. Braun offer neurosurgical, monitoring, and spinal products. Abbott leads in point-of-care TBI blood testing. ONWARD Medical, NervGen, and Amphix Bio are building neuromodulation and regenerative options.

Competition is shifting from acute stabilization toward recovery and function. Companies are adding diagnostics, neuromodulation, and drug candidates to complement surgery. Abbott's longer-term goal is a test for non-healthcare settings, such as sports sidelines. Evidence and reimbursement will decide winners. Players with strong clinical data, trauma center relationships, and home-use options are better placed to grow.

Key Industry Developments:

• In April 2026, NervGen Pharma announced that it had completed an end-of-Phase II meeting with the U.S. Food and Drug Administration (FDA) and reached alignment on the proposed design of RESTORE, a planned Phase III registrational study of NVG-291 for chronic tetraplegia. The proposed 16-week study will assess changes in hand function using the GRASSP Quantitative Prehension measure, alongside patient and clinician assessments.
• In April 2026, Oragenics announced that the first patient had received ONP-002 in its Phase IIa clinical trial for concussion and mild traumatic brain injury at Mackay Base Hospital in Australia. The investigational treatment uses an intranasal dry-powder delivery system intended to deliver a neuroprotective agent to the brain. The trial is designed to evaluate the treatment's potential to address post-injury inflammation, oxidative stress and cerebral swelling, with the initial study planned to enroll 40 patients.
• In March 2026, the University of Louisville and UofL Health launched FLUID-TBI, a multidisciplinary clinical trial investigating whether the type of intravenous fluid administered during the initial treatment of severe traumatic brain injury affects survival and neurological recovery. The study addresses an important question in emergency and intensive care as IV fluids are routinely used to maintain circulation after severe head trauma, but their comparative effects on longer-term brain recovery remain uncertain.